JX-594: A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma

JX-594 is a targeted and granulocyte-macrophage colony stimulating factor (GM-CSF) expressing oncolytic poxvirus designed to selectively replicate in and destroy cancer cells through viral oncolysis and tumor-specific immunity. In this trial, JX-594 and sorafenib, a small molecule inhibitor of B-raf and vascular endothelial growth factor receptor (VEGFR), resulted in significantly decreased tumor perfusion, and up to 100% necrosis of tumor tissue. I like this approach because JX-594 has the ability to selectively reproduce in tumor tissues and since this approach targets the EGFR-RAS-VEGFR pathways, it can be used to treat many different types of cancers.

Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy


Speak Your Mind

*